Testing effectiveness (Phase 2)Looking for participantsNCT05431270
What this trial is testing
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Who this might be right for
Non Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phanes Therapeutics 40